Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytotoxic T lymphocyte-mediated cytolysis is the primary mechanism by which CD8+ T cells destroy virus-infected, cancerous, or otherwise abnormal cells. Upon activation, CTLs recognize antigenic peptides presented on MHC class I molecules via their T cell receptor (TCR) and receive additional co-stimulatory signals (e.g., via CD28). Activated CTLs release cytolytic granules containing perforin and granzymes, which induce target cell apoptosis. Alternatively, CTLs induce death through the Fas-Fas ligand pathway. Cytolysis is essential for immune surveillance and elimination of threats, but dysregulation can contribute to tissue damage and autoimmune disease[6][5][2][3][1][4][7].
Enhancement of CTL activity (e.g. by cytokines or checkpoint blockade); Inhibition of T cell activation (immunosuppressants)
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Direct cytolysis by cytotoxic T lymphocyte activation (CTL).